How Anne Wojcicki Kept 23andMe Alive Through Regulatory Fire

Episode notes

Episode 64 of The CEO Diary examines how Anne Wojcicki navigated 23andMe through a near-fatal FDA shutdown in 2013, rebuilt trust with regulators, and transformed the company from a consumer genetics novelty into a research-driven platform. Lucas and Luna break down the specific moment the FDA ordered 23andMe to stop selling its health reports, Wojcicki's decision to cut 20 percent of staff and refocus on research partnerships, and how she eventually secured FDA approval for direct-to-consumer genetic health tests. They also discuss the trade-offs between Wojcicki's long-term vision and the pressure to deliver quarterly profits, and what the 23andMe story reveals about startup resilience when your entire business model runs headfirst into a regulator. This episode is a case study in founder grit, regulatory strategy, and the art of keeping a company alive long enough to prove its skeptics wrong.